Galectin Therapeutics (PHPN) AI Stock Analysis

Galectin Therapeutics

(Frankfurt:PHPN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt ReductionThe conversion materially reduces reported debt and interest obligations, strengthening the capital structure from a highly leveraged base. It also reflects continued support from the largest shareholder and may preserve more financial capacity for advancing belapectin programs over the next several quarters.

Negative Factors

No Revenue and Persistent LossesThe absence of revenue means the business currently lacks operating income to fund research and development. Persistent EBIT and net losses leave results dependent on financing or other capital sources, making future progress vulnerable if clinical spending continues without commercial receipts.

Galectin Therapeutics (PHPN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 218.64M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -7.8
Beta (1Y): -0.53
Revenue Growth: ―
EPS Growth: 37.95%
Country: Germany
Employees: 9
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Galectin Therapeutics Business Overview & Revenue Model

Company Description

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship th...

Galectin Therapeutics Risk Analysis

Galectin Therapeutics disclosed 37 risk factors in its most recent earnings report. Galectin Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Galectin Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PHPN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	48Neutral	$1.33B	9.65	-109.40%	―	―	―
TECX	46Neutral	$386.69M	-4.33	-35.26%	―	―	-13.09%
TNYA	40Underperform	$83.74M	-0.69	-108.05%	―	―	45.08%
JBIO	37Underperform	$894.18M	-5.11	-49.11%	―	―	91.41%
VYGR	37Underperform	$105.98M	-0.95	-57.92%	―	-19.07%	2.07%

* Healthcare Sector Average

Performance Comparison

DE:PHPN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PHPN	Galectin Therapeutics (GALT)	2.84	-2.10	-42.51%
OMER	Omeros Corporation	18.44	11.27	157.18%
VYGR	Voyager Therapeutics Inc.	1.72	-2.87	-62.53%
TECX	Tectonic Therapeutic Inc	19.78	2.27	12.96%
JBIO	Jade Biosciences, Inc.	14.06	4.59	48.47%
TNYA	Tenaya Therapeutics, Inc.	0.37	-1.06	-74.34%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Galectin Therapeutics AI Stock Analysis